EOLS Share Price Performance
US$0
-7.43 (-100.00%)
Price US$0
Fair ValueUS$14.67
Share Pricen/a
Narrative Update • Aug 20
Evolus, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 31 Fair Values set on narratives written by author
EOLS Community Narratives
AN
Fair Value
·Fair Value US$14.67 42.8% undervalued intrinsic discount
International Expansion And Pipeline Developments Will Reshape Aesthetics Markets
2users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value
·Fair Value US$12 30.1% undervalued intrinsic discount
Cash Pay Aesthetics Exposure Will Test Injectable Demand Yet Long Term Potential Remains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$20 58.1% undervalued intrinsic discount
Rewards Scale And Medical Education Will Drive Aesthetics Portfolio Higher Over The Long Term
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Cash Pay Aesthetics Exposure Will Test Injectable Demand Yet Long Term Potential Remains
Evolus sells wrinkle and filler treatments that people pay for out of pocket, which can do well when shoppers feel confident but can slow fast when budgets get tight. The big question is whether its newer filler lineup and clinic bundling efforts can keep demand steady while tariffs, regulation timelines, and a softer procedure market test growth.Read more
AN
US$12
30.1% undervalued intrinsic discount
Fair Value
Profit Margin
21.93%
Future PE
9.94x
Price in 2029
US$14.61
International Expansion And Pipeline Developments Will Reshape Aesthetics Markets
Evolus is trying to reduce its reliance on a single flagship wrinkle-treatment by pushing into more countries and rolling out new products that could broaden its customer base. The big question is whether demand for cosmetic procedures rebounds soon enough—and whether newer launches turn into steady repeat sales rather than a short-lived early spike.Read more
AN
US$14.67
42.8% undervalued intrinsic discount
Fair Value
Profit Margin
5.54%
Future PE
47.14x
Price in 2029
US$17.89
Rewards Scale And Medical Education Will Drive Aesthetics Portfolio Higher Over The Long Term
Catalysts About Evolus Evolus is a performance beauty company focused on cash pay injectable aesthetics, including neurotoxin and hyaluronic acid filler products. What are the underlying business or industry changes driving this perspective?Read more
AN
US$20
58.1% undervalued intrinsic discount
Fair Value
Profit Margin
26.17%
Future PE
11.6x
Price in 2029
US$25.51
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
EOLS: Index Inclusion And Injectables Expansion Will Support Bullish Multiyear Outlook
Fair Value: US$12 30.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EOLS: International Filler Expansion Will Support Future Share Price Re Rating
Fair Value: US$14.67 42.8% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rewards Scale And Medical Education Will Drive Aesthetics Portfolio Higher Over The Long Term
Fair Value: US$20 58.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Evolus, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.52
- 66.74%
- -10.85%
- -507.2%
About EOLS
- Founded
- 2012
- Employees
- 353
- CEO
- WebsiteView website
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Recent EOLS News & Updates
Seeking Alpha • Aug 11
Evolus: The Injectable Platform Is Becoming The Real Moat
Summary Evolus is evolving into a multi-product aesthetics platform, leveraging its distribution network and loyalty ecosystem to drive operating leverage and recurring revenue. Q2 2026 results showed 21% revenue growth, positive adjusted EBITDA, and raised guidance, with management projecting 2028 revenue of $450M–$500M and EBITDA margins of 13–15%. Evolus trades at a forward EV/Sales of 1.86, a 50% discount to sector median, but requires margin expansion to justify valuation as it transitions from single-product to platform economics. Execution risks include consumer demand sensitivity, intense competition, balance sheet leverage, and regulatory timing for pipeline products like Evolysse Sculpt and Profhilo. Read the full article on Seeking AlphaNarrative Update • Aug 06
